Silverarc Capital Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Silverarc Capital Management’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$34.6M	Buy	311,461 +5,461	+2%	+$494K	3.59%	7
2026 Q1	$26.6M	Buy	306,000 +170,050	+125%	+$16.5M	2.72%	14
2025 Q4	$14.6M	Sell	135,950 -234,046	-63%	-$24.8M	2.02%	16
2025 Q3	$37.4M	Sell	369,996 -30,776	-8%	-$2.86M	5.04%	2
2025 Q2	$25.3M	Buy	400,772 +63,167	+19%	+$3.87M	4.67%	5
2025 Q1	$17.9M	Buy	337,605 +63,709	+23%	+$3.53M	3.66%	8
2024 Q4	$15.3M	Buy	273,896 +18,318	+7%	+$1.01M	3.35%	11
2024 Q3	$13.4M	Buy	255,578 +70,916	+38%	+$3.4M	3.01%	8
2024 Q2	$7.58M	Buy	184,662 +886	+0.5%	+$35.4K	1.79%	19
2024 Q1	$7.96M	Buy	183,776 +9,528	+5%	+$417K	2.21%	14
2023 Q4	$8.01M	Sell	174,248 -86,289	-33%	-$2.72M	2.38%	14
2023 Q3	$5.97M	Buy	260,537 +144,369	+124%	+$3.23M	1.81%	21
2023 Q2	$1.92M	Buy	+116,168	New	+$2.1M	0.59%	47

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silverarc Capital Management's RYTM Position: Q2 2026 in Review

Silverarc Capital Management increased its Rhythm Pharmaceuticals (RYTM) stake by 1.8% in Q2 2026, buying an estimated $494K and bringing the position to 311,461 shares worth $34.6M. The position accounts for 3.59% of the portfolio, ranked #7.

Silverarc Capital Management first reported a position in RYTM in Q2 2023 and has held it in 13 quarters since. The position peaked at $37.4M in Q3 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Silverarc Capital Management held 311,461 shares of Rhythm Pharmaceuticals worth $34.6M as of Q2 2026.
Silverarc Capital Management bought 5,461 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $494K.
Rhythm Pharmaceuticals made up 3.59% of Silverarc Capital Management's portfolio in Q2 2026, its #7 holding.
Silverarc Capital Management first reported a position in Rhythm Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Silverarc Capital Management's Rhythm Pharmaceuticals position peaked at $37.4M in Q3 2025.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.